If i might comment on this also. It seems the company gets patient reports without the info of what group the patient is in, .. treated or placebo. So if they see a large portion of good signs that should not be visible it would be a good sign. 

Ie egfr should be low in most kidney group so if the egfr goes up in many of that group the company should know that the drug is working as egfr rates in the placebo should all remain low. BearDownAZ posted other indicators that should not change in the placebo kidney group.